Unknown

Dataset Information

0

Excitatory neuron-specific SHP2-ERK signaling network regulates synaptic plasticity and memory.


ABSTRACT: Mutations in RAS signaling pathway components cause diverse neurodevelopmental disorders, collectively called RASopathies. Previous studies have suggested that dysregulation in RAS-extracellular signal-regulated kinase (ERK) activation is restricted to distinct cell types in different RASopathies. Some cases of Noonan syndrome (NS) are associated with gain-of-function mutations in the phosphatase SHP2 (encoded by PTPN11); however, SHP2 is abundant in multiple cell types, so it is unclear which cell type(s) contribute to NS phenotypes. Here, we found that expressing the NS-associated mutant SHP2D61G in excitatory, but not inhibitory, hippocampal neurons increased ERK signaling and impaired both long-term potentiation (LTP) and spatial memory in mice, although endogenous SHP2 was expressed in both neuronal types. Transcriptomic analyses revealed that the genes encoding SHP2-interacting proteins that are critical for ERK activation, such as GAB1 and GRB2, were enriched in excitatory neurons. Accordingly, expressing a dominant-negative mutant of GAB1, which reduced its interaction with SHP2D61G, selectively in excitatory neurons, reversed SHP2D61G-mediated deficits. Moreover, ectopic expression of GAB1 and GRB2 together with SHP2D61G in inhibitory neurons resulted in ERK activation. These results demonstrate that RAS-ERK signaling networks are notably different between excitatory and inhibitory neurons, accounting for the cell type-specific pathophysiology of NS and perhaps other RASopathies.

SUBMITTER: Ryu HH 

PROVIDER: S-EPMC6800025 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications


Mutations in RAS signaling pathway components cause diverse neurodevelopmental disorders, collectively called RASopathies. Previous studies have suggested that dysregulation in RAS-extracellular signal-regulated kinase (ERK) activation is restricted to distinct cell types in different RASopathies. Some cases of Noonan syndrome (NS) are associated with gain-of-function mutations in the phosphatase SHP2 (encoded by <i>PTPN11</i>); however, SHP2 is abundant in multiple cell types, so it is unclear  ...[more]

Similar Datasets

| S-EPMC5515925 | biostudies-literature
| S-EPMC6884593 | biostudies-literature
| S-EPMC3498958 | biostudies-literature
| S-EPMC3740594 | biostudies-literature
| S-EPMC5710002 | biostudies-literature
| S-EPMC1446931 | biostudies-literature
2023-04-17 | GSE208149 | GEO
2013-03-24 | E-GEOD-44229 | biostudies-arrayexpress
| S-EPMC3777648 | biostudies-literature
| S-EPMC3400572 | biostudies-literature